Gabapentin
Product Images NDC 50090-2561

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 50090-2561). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1 (Image 1)

The text represents an equation to calculate cLcr (creatinine clearance) for male patients and female patients. The equation takes into account the patient's age and weight in kilograms, and the serum creatinine level in milligrams per deciliter.*

FDA Label Image

1 (Image 2)

FDA Label Image

1 (Image 3)

FDA Label Image

1 (Image 4)

FDA Label Image

1 (Image 5)

FDA Label Image

1 (Image 6)

This appears to be a chart or graph displaying the mean pain score for a study that involved a dose titration period followed by a 4-week fixed dose period. The two treatment options indicated are a placebo and a dosage of gabapentin at 3600 mg/day. There is also a baseline measurement period and the duration of the study is indicated as being multiple weeks. No further information is available.*

FDA Label Image

2 (Image 7)

This appears to be a chart or table related to pain management. It includes information on mean pain score and different dosages of Gabapentin administered over a fixed period of four weeks. However, without further context or information, it is difficult to provide a full description of the purpose or significance of this data.*

FDA Label Image

3 (Image 8)

FDA Label Image

4 (Image 9)

FDA Label Image

Label Image (Lbl500902561)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.